The New World Primate, Aotus Nancymae, As a Model for Examining the Immunogenicity of a Prototype Enterotoxigenic Escherichia Coli Subunit Vaccine.
From: Bacterial Diseases Program, Naval Medical Research Center Detachment (NMRCD-Lima, Peru), NMRCD Unit 3800, APO, AA 34031, Peru. jonesf@nmrc.navy.mil
Vaccine
- Publish Date: May 2006
- ISSN: 0264-410X
- Volume: 24
- Issue: 18
- Pages: 3786-92
- Medium: Print
- Language: English
- Citation (JAMA): Jones Franca R, Hall Eric R, Tribble David, et al. The New World Primate, Aotus Nancymae, As a Model for Examining the Immunogenicity of a Prototype Enterotoxigenic Escherichia Coli Subunit Vaccine.. Vaccine May 2006;24:3786-92
Abstract
The colonization factors (CF) of enterotoxigenic Escherichia coli (ETEC) are being targeted for inclusion in a multi-subunit ETEC vaccine. This study was designed to examine the preclinical safety and immunogenicity of CF CS6, encapsulated in a biodegradable poly(DL-lactide-co-glycolide) (meCS6), and administered in the presence or absence of a mutated heat-labile enterotoxin, LT(R192G), in the non-human primate, Aotus nancymae. A. nancymae were inoculated intranasally (IN) with meCS6 (200 microg; positive control), or intragastrically (IG) with meCS6 (200 or 1000 microg) with or without 2 microg LT(R192G) in three doses given at 2-week intervals. In a second experiment, A. nancymae were inoculated IG with 950 microg of meCS6 with or without 2 microg LT(R192G) in four doses given every 48 h. Blood was collected to assess anti-CS6 and -LT serum immunoglobulin G (IgG) and IgA responses and safety variables (complete blood count and chemistry). Safety parameters were unchanged from baseline following all vaccinations. In Experiment 1, a dose-related serologic response to CS6 was observed; 78.6 and 57.1% of monkeys given 1000 microg meCS6 (n = 14) had a serum IgG and IgA response, respectively, compared to only 28.6% of monkeys given 200 microg meCS6 (n = 14) with a serum IgG and IgA response. No significant effect on the number of responders or the magnitude of responses was observed with the addition of LT(R192G). The three-dose, 2-week regimen with 1000 microg meCS6 was more effective at eliciting an immune response than the four-dose, 48-h regimen with 950 microg meCS6. Results from this study indicate that A. nancymae provide a useful ETEC preclinical safety and immunogenicity model.
Mesh Headings (Keywords): Adjuvants, Immunologic, Administration, Intranasal, Animals, Antibodies, Bacterial, Antigens, Bacterial, Aotidae, Bacterial Toxins, Blood Cell Count, Blood Chemical Analysis, Enterotoxins, Escherichia coli, Escherichia coli Infections, Escherichia coli Proteins, Escherichia coli Vaccines, Female, Gastric Lavage, Immunoglobulin A, Immunoglobulin G, Lactic Acid, Male, Models, Animal, Mutation, Polyglycolic Acid, Polymers, Vaccines, Subunit
Check for Full Text / PubMed Unique Identifier (PMID): 16343702
This abstract is part of PubMed, a service of the U.S. National Library of Medicine. PubMed includes more than 17 million citations from MEDLINE and other life science journals for biomedical articles. See Copyright and Disclaimers.
Linked medical terms appearing on this page are added by Healia to help readers find more information and are not part of the original PubMed document.
The data herein was last updated on July 8th, 2008 and may not reflect the most current and accurate data available from NLM.